Clelia Madeddu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1888185/clelia-madeddu-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132
papers3,832
citations36
h-index59
g-index144
ext. papers4,414
ext. citations3.8
avg, IF5.3
L-index

#	Paper	IF	Citations
132	Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review <i>Diagnostics</i> , 2022 , 12,	3.8	О
131	Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. <i>Diagnostics</i> , 2021 , 11,	3.8	0
130	Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique. <i>BMC Surgery</i> , 2021 , 21, 380	2.3	
129	Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
128	Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE trial <i>Journal of Clinical Oncology</i> , 2021 , 39, e15503-e15503	2.2	
127	Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 593-611	3	2
126	Alcohol Consumption Is a Modifiable Risk Factor for Breast Cancer: Are Women Aware of This Relationship?. <i>Alcohol and Alcoholism</i> , 2021 ,	3.5	1
125	Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports. <i>World Journal of Clinical Cases</i> , 2021 , 9, 5655-5660	1.6	
124	Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity. <i>Antioxidants and Redox Signaling</i> , 2021 , 34, 572-588	8.4	4
123	Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5[kg to 11.000[kg. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 169-179	2.5	2
122	Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103167	7	12
121	COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. <i>Journal of Ovarian Research</i> , 2021 , 14, 28	5.5	5
120	Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer. <i>Diagnostics</i> , 2021 , 11,	3.8	4
119	The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review <i>Clinical Practice and Epidemiology in Mental Health</i> , 2021 , 17, 295-306	3.2	0
118	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	12
117	Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. <i>Scientific Reports</i> , 2020 , 10, 6096	4.9	57
116	Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report. World Journal of Clinical Cases, 2020 , 8, 3527-3533	1.6	2

Blocking inflammation to improve immunotherapy of advanced cancer. *Immunology*, **2020**, 159, 357-3647.8 115 13 Multifactorial pathogenesis of COVID-19-related coaquiopathy: Can defibrotide have a role in the 114 15.4 7 early phases of coagulation disorders?. Journal of Thrombosis and Haemostasis, 2020, 18, 3106-3108 Defibrotide in the COVID-19 coagulopathy: What is the timing?. Journal of Thrombosis and 113 15.4 2 Haemostasis, 2020, 18, 3113-3115 Systemic therapy for the treatment of endometrial cancer. Expert Opinion on Pharmacotherapy, 112 4 **2019**, 20, 2019-2032 The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone. 111 7.5 5 International Journal of Cancer, **2019**, 145, 2594-2596 Laparoscopic hysterectomy as optimal approach for 5400 grams uterus with associated 1.6 4 polycythemia: A case report. World Journal of Clinical Cases, 2019, 7, 3027-3032 Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. Oncotarget, 109 2 3.3 2019, 10, 2012-2021 An interdisciplinary approach for laparoscopic removal of a large retroperitoneal pelvic 108 1.8 schwannoma attached to vital vessels: A case report. Medicine (United States), 2019, 98, e18149 Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related 6.6 107 24 anemia in advanced ovarian cancer: key role of interleukin-6. Haematologica, 2018, 103, e388-e391 Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine 106 1.7 manipulator: description of emblematic cases. Gynecological Surgery, 2018, 15, 6 Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in 105 13.4 4 Patients With Sarcomas. JAMA Oncology, 2018, 4, 1134 Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted 104 4.6 48 Mechanism-Based Approach. Frontiers in Physiology, 2018, 9, 1294 Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link?. 6.5 103 15 European Journal of Endocrinology, 2017, 177, 85-92 Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair 102 3.7 MDM2-p53 complex formation. Journal of Antibiotics, 2017, 70, 962-966 Energy expenditure in caving. PLoS ONE, 2017, 12, e0170853 101 9 3.7 Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report. International Journal of Surgery Case 0.8 6 Reports, 2017, 38, 107-110 Laparoscopic removal of a very large uterus weighting 5320 g is feasible and safe: a case report. 99 2.3 9 BMC Surgery, 2017, 17, 50 Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline 98 8 chemotherapy. International Journal of Cardiovascular Imaging, 2017, 33, 197-207

97	Validation of the CAchexia SCOre (CASCO). Staging Cancer Patients: The Use of miniCASCO as a Simplified Tool. <i>Frontiers in Physiology</i> , 2017 , 8, 92	4.6	28
96	Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience <i>Journal of Clinical Oncology</i> , 2017 , 35, e17540-e17540	2.2	
95	Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up. <i>Journal of Minimally Invasive Gynecology</i> , 2016 , 23, 1003-8	2.2	2
94	Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17 Suppl 1, S12-8	1.9	50
93	Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman. <i>Journal of Obstetrics and Gynaecology</i> , 2016 , 36, 1012-1015	1.3	
92	Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures. <i>Archives of Gynecology and Obstetrics</i> , 2016 , 294, 525-31	2.5	21
91	Endodontic infection and endothelial dysfunction are associated with different mechanisms in men and women. <i>Journal of Endodontics</i> , 2015 , 41, 594-600	4.7	23
90	Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. <i>International Journal of Cardiology</i> , 2015 , 191, 203-10	3.2	25
89	Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. <i>Future Oncology</i> , 2015 , 11, 2697-2710	3.6	18
88	Advances in pharmacologic strategies for cancer cachexia. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2163-77	4	21
87	A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2015 , 50, e1-4	4.8	6
86	Surprising results of a supportive integrated therapy in myelofibrosis. <i>Nutrition</i> , 2015 , 31, 239-43	4.8	4
85	The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. <i>Haematologica</i> , 2015 , 100, 124-32	6.6	114
84	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: Preliminary results <i>Journal of Clinical Oncology</i> , 2015 , 33, e13501-e13501	2.2	
83	High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts. <i>Scientific Reports</i> , 2015 , 5, 17812	4.9	7
82	Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. Journal of Cellular and Molecular Medicine, 2014 , 18, 2519-29	5.6	46
81	Large twisted ovarian fibroma associated with MeigsRsyndrome, abdominal pain and severe anemia treated by laparoscopic surgery. <i>BMC Surgery</i> , 2014 , 14, 38	2.3	13
80	Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases. <i>Oncology Letters</i> , 2014 , 8, 1279-1282	2.6	10

79	A combined treatment approach for cachexia and cancer-related anemia in advanced cancer patients: A randomized placebo-controlled trial <i>Journal of Clinical Oncology</i> , 2014 , 32, 189-189	2.2	3
78	Taxane associated with trastuzumab-induced early ventricular impairment: Correlation with biologic markers of chronic inflammation and oxidative stress <i>Journal of Clinical Oncology</i> , 2014 , 32, e11566-e11566	2.2	
77	Cisplatin: an old drug with a newfound efficacy from mechanisms of action to cytotoxicity. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1839-57	4	62
76	Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate. <i>SpringerPlus</i> , 2013 , 2, 198		51
75	Treatment of irradiated expanders: protective lipofilling allows immediate prosthetic breast reconstruction in the setting of postoperative radiotherapy. <i>Aesthetic Plastic Surgery</i> , 2013 , 37, 1146-52	2	50
74	The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implicationsa review. <i>Journal of Molecular Medicine</i> , 2013 , 91, 1355-68	5.5	44
73	Current medications for cancer cachexia 2013 , 34-45		
72	Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. <i>Drug Design, Development and Therapy</i> , 2013 , 7, 645-56	4.4	14
71	Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice <i>Journal of Clinical Oncology</i> , 2013 , 31, e20556-e20556	2.2	
70	A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. <i>Gynecologic Oncology</i> , 2012 , 124, 417-25	4.9	96
69	Inflammation and ovarian cancer. <i>Cytokine</i> , 2012 , 58, 133-47	4	196
68	Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 286, 1209-14	2.5	12
67	L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. <i>Clinical Nutrition</i> , 2012 , 31, 889-95	5.9	29
66	Antioxidants, Anorexia/Cachexia, and Oxidative Stress in Patients with Advanced-Stage Cancer 2012 , 373-385		
65	Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical approach. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 285, 1577-80	2.5	4
64	Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. <i>Clinical Nutrition</i> , 2012 , 31, 176-82	2 ^{5.9}	89
63	Cachexia and oxidative stress in cancer: an innovative therapeutic management. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4813-8	3.3	16
62	Current pharmacotherapy options for cancer anorexia and cachexia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2453-72	4	33

61	Management of anemia of inflammation in the elderly. Anemia, 2012, 2012, 563251	1.6	30
60	Multitargeted treatment of cancer cachexia. <i>Critical Reviews in Oncogenesis</i> , 2012 , 17, 305-14	1.3	18
59	Krill oil to improve blood lipids status in advanced cancer patient with cachexia <i>Journal of Clinical Oncology</i> , 2012 , 30, e19634-e19634	2.2	О
58	Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and myocardial dysfunction <i>Journal of Clinical Oncology</i> , 2012 , 30, 9006	5- 3 -306	
57	Association of endodontic infection with detection of an initial lesion to the cardiovascular system. Journal of Endodontics, 2011 , 37, 1624-9	4.7	53
56	Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. <i>Scientific World Journal, The</i> , 2011 , 11, 2020-36	2.2	64
55	Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 1003-1009	2.1	44
54	Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010 , 3, 165-172	1.3	7
53	Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. <i>Oncologist</i> , 2010 , 15, 894-902	5.7	41
52	Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. <i>Oncologist</i> , 2010 , 15, 200-11	5.7	146
51	Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2010 , 4, 259	9-65	6
50	Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. <i>American Heart Journal</i> , 2010 , 160, 48	7. 1 e9-7	111
49	Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. <i>Journal of Molecular Medicine</i> , 2010 , 88, 85-92	5.5	97
48	Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. <i>Journal of Molecular Medicine</i> , 2010 , 88, 677-86	5.5	77
47	Cancer cachexia: medical management. Supportive Care in Cancer, 2010, 18, 1-9	3.9	54
46	Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010 , 3, 165-172	1.3	4
45	New perspective on the nutritional approach to cancer-related anorexia/cachexia: preliminary results of a randomised phase III clinical trial with five different arms of treatment. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009 , 2, 29-36	1.3	1
44	Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3951-9	5.6	31

(2006-2009)

43	results of a randomised phase III clinical trial with five different arms of treatment. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009 , 2, 29-36	1.3	1
42	Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease. <i>British Journal of Haematology</i> , 2009 , 146, 335-7	4.5	10
41	patients who have failed to respond to a previous antiemetic treatment: comparison between	7	26
40	elderly and non-elderly patient response. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 70, 83-91 Medroxyprogesterone acetate in the management of cancer cachexia. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1359-66	4	36
39	Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 693-703	4	16
38	An update on promising agents for the treatment of cancer cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2009 , 3, 258-62	2.6	14
37	Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. <i>Nutrition</i> , 2008 , 24, 305-13	4.8	74
36	Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. <i>Oncologist</i> , 2008 , 13, 1296-305	5.7	35
35	Evidence that human serum with high levels of estrogens interferes with immune system both by decreasing CD25 expression on T-cell and by increasing interleukin-2 availability. <i>Reproductive Sciences</i> , 2008 , 15, 961-9	3	2
34	Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia. <i>Current Opinion in Supportive and Palliative Care</i> , 2008 , 2, 275-81	2.6	17
33	Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2008 , 26, 98-103	1.3	41
32	An attempt to correlate a "Multidimensional Geriatric Assessment" (MGA), treatment assignment and clinical outcome in elderly cancer patients: results of a phase II open study. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 75-83	7	29
31	An Innovative Treatment Approach for Cancer-Related Anorexia/Cachexia and Oxidative Stress: Background and Design of an Ongoing, Phase III, Randomized Clinical Trial. <i>Supportive Cancer Therapy</i> , 2007 , 4, 163-7		2
30	Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. <i>Oncologist</i> , 2007 , 12, 1124-33	5.7	107
29	Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer-Related Anorexia/Cachexia. <i>Current Nutrition and Food Science</i> , 2007 , 3, 184-193	0.7	4
28	Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects. <i>Journal of Vascular Research</i> , 2007 , 44, 253-63	1.9	22
27	Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. <i>Nutrition</i> , 2006 , 22, 136-45	4.8	137
26	A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiology Biomarkers and	4	124

25 Proinflammatory Cytokines: Their Role in Multifactorial Cancer Cachexia **2006**, 477-482

1

- A Phase II Study with Antioxidants, both in the Diet and Supplemented, Pharmaco-Nutritional Support, Progestagen and Anti-COX-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia-Cachexia and Oxidative Stress **2006**, 685-698
- 23 Immunological Parameters of Nutrition 2006, 111-124

22	Glucose Metabolism 2006 , 195-203		2
21	Oxidative Stress and Cancer Cachexia 2006 , 733-759		2
20	Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 175-82	7	57
19	Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. <i>Blood</i> , 2005 , 106, 362-7	2.2	100
18	Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity. <i>Journal of Experimental Therapeutics and Oncology</i> , 2004 , 4, 69-78	0.8	17
17	Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 1651-9	4	44
16	Cancer-related cachexia and oxidative stress: beyond current therapeutic options. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 381-92	3.5	11
15	Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. <i>Oncology Reports</i> , 2003 , 10, 197	3.5	2
14	Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. <i>Journal of Molecular Medicine</i> , 2003 , 81, 664-73	5.5	95
13	Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003 , 3, 205-19	0.8	22
12	The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. <i>Free Radical Research</i> , 2003 , 37, 213-23	4	68
11	Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2003 , 22, 17-28	2.1	45
10	Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. <i>International Journal of Cancer</i> , 2002 , 98, 84-97	1 ^{7.5}	115
9	Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity 2002 , 20, 419		2
8	Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. <i>Oncology Reports</i> , 2002 , 9, 661	3.5	

LIST OF PUBLICATIONS

7	Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. <i>Oncology Reports</i> , 2002 , 9, 887	3.5	1
6	Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. <i>Oncology Reports</i> , 2002 , 9, 661-70	3.5	6
5	Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. <i>Oncology Reports</i> , 2002 , 9, 887-96	3.5	12
4	Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. <i>Journal of Molecular Medicine</i> , 2001 , 79, 406-14	5.5	70
3	Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 2001 , 18, 383		1
2	Managing cancer-related anorexia/cachexia. <i>Drugs</i> , 2001 , 61, 499-514	12.1	129
1	Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. <i>Journal of Molecular Medicine</i> , 2000 , 78, 554-61	5.5	165